Neurology Medical News about Menstrual Cycle Migraine Disorders Frovatriptan

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Safety and Tolerability of Short-Term Preventive Frovatriptan: A Combined Analysis
Headache: The Journal of Head and Face Pain, 10/15/09

MacGregor AE et al. – During treatment of up to 12 perimenstrual periods over a 12– to 15–month period, the safety and tolerability of frovatriptan for short–term prevention of menstrual migraine was similar to that observed with acute use of triptans. Adverse events were generally mild or moderate in severity, there was no evidence of an increased risk of cardiovascular adverse events relative to acute treatment, and rebound headache was not evident. A short–term regimen with frovatriptan presents a safe and viable treatment option for preventing predictable migraine such as menstrual migraine.

<< Previous
Zolmitriptan Nasal Spray in the Acute Treatment of Cluster...

Next >>
Augmented Cerebral Activation by Lumbar Mechanical Stimulus in...